Sugi Predict

Sugi Predict / Compounds / SCHEMBL671541

SCHEMBL671541

SCHEMBL671541

CC(C)(C)OC(=O)n1cc(N)cn1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ROCK2 O75116 1/20 0.45
▸ SCD O00767 1/20 0.42
▸ NR1H2 P55055 2/20 0.38
▸ ELANE P08246 2/20 0.35
▸ BCHE P06276 1/20 0.34
▸ HSP90AA1 P07900 1/20 0.34
▸ HSP90AB1 P08238 1/20 0.34
▸ HTT P42858 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ FAAH O00519 1/20 0.33
▸ GPR119 Q8TDV5 3/20 0.32
▸ MAP4K4 O95819 1/20 0.32
▸ PLAU P00749 1/20 0.32
▸ USP2 O75604 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15742917 0.82 ROCK2 (0.60) ROCK2SCDNR1H2GPR119
SCHEMBL17648499 0.81 ROCK2 (0.43) ROCK2SCDNR1H2ELANEBCHE
SCHEMBL427252 0.81 NOS1 (0.46) ROCK2SCDELANEBCHEGPR119
SCHEMBL16566336 0.80 KDM4E (0.36) —
SCHEMBL23607874 0.79 ROCK2 (0.42) ROCK2SCDNR1H2SMN1; SMN2
SCHEMBL14911064 0.79 ROCK2 (0.49) ROCK2SCDNR1H2GPR119
SCHEMBL1206008 0.79 ROCK2 (0.45) ROCK2SCDNR1H2ELANEBCHE
SCHEMBL18083986 0.79 ROCK2 (0.43) ROCK2SCDNR1H2ELANEBCHE
SCHEMBL2549524 0.79 ELANE (0.47) ROCK2SCDNR1H2ELANEBCHE
SCHEMBL11901149 0.79 ROCK2 (0.43) ROCK2SCDNR1H2ELANEBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 305 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124205-A1 MODULATORS OF BETA CATENIN AND USES THEREOF DEWPOINT THERAPEUTICS INC (US) 2026-05-07 — — US disclosed
EP-4735114-A1 SUBSTITUTED THIENO [3,2-B]PYRIDINES AS INHIBITORS OF PROTEIN KINASES Masarykova Univerzita (CZ) 2026-05-06 — — EP disclosed
WO-2026090104-A1 MODULATORS OF BETA CATENIN AND USES THEREOF DEWPOINT THERAPEUTICS, INC. (US) 2026-04-30 — — WO disclosed
US-12595253-B2 Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2026-04-07 — — US disclosed
EP-4712961-A2 KRAS G12S AND G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2026-03-25 — — EP disclosed
US-12522619-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2026-01-13 — — US disclosed
WO-2025264959-A1 SUBSTITUTED PYRAZOLOPYRIDINES AS PHOSPHOINOSIDIDE KINASE (PIK) MODULATORS RECURSION PHARMACEUTICALS, INC. (US) 2025-12-26 — — WO disclosed
EP-4663630-A1 NOVEL BENZIMIDAZOLONE DERIVATIVE COMPOUND AS AUTOTAXIN INHIBITOR LG Chem, Ltd. (KR) 2025-12-17 — — EP disclosed
US-20250333424-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2025-10-30 — — US disclosed
CN-118994015-B Bipyrazolyl azo compound 上海交通大学绍兴新能源与分子工程研究院 2025-10-21 — — CN disclosed
WO-2011036280-A1 BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 — — WO disclosed
US-20110076292-A1 BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 — — US disclosed
US-20100298301-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2010-11-25 — — US disclosed
US-20100298301-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2010-11-25 — — US disclosed
US-20100298301-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2010-11-25 — — US disclosed
WO-2010055304-A2 PHARMACEUTICAL COMPOUNDS SAREUM LIMITED (GB) 2010-05-20 — — WO disclosed
EP-2170849-A1 OXAZOLE TYROSINE KINASE INHIBITORS Sareum Limited (GB) 2010-04-07 — — EP disclosed
WO-2010010184-A1 [1, 2, 4] TRIAZOLO [1, 5-A] PYRIDINES AS JAK INHIBITORS GALAPAGOS NV (BE) 2010-01-28 — — WO disclosed
US-20090325956-A1 Aromatic amine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-31 — — US disclosed
WO-2008139161-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2008-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325956-A1 Aromatic amine derivative and use thereof SCD, SCD5, SMS ROCK2 2056/4885SCD 1/4885NR1H2 7/4885
US-12595253-B2 Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof JAK1, JAK3, JAK2 ROCK2 675/4885SCD 3963/4885NR1H2 1869/4885
US-20260124205-A1 MODULATORS OF BETA CATENIN AND USES THEREOF CTNNB1, CTNNA1, CTNND1 ROCK2 3841/4885SCD 1897/4885NR1H2 37/4885
US-20250333424-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, IRF3 ROCK2 3458/4885SCD 2313/4885NR1H2 3119/4885
US-20110076292-A1 BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE BMX, PIK3CA, PI4KA ROCK2 1180/4885SCD 3309/4885NR1H2 201/4885
US-20100298301-A1 OXAZOLE TYROSINE KINASE INHIBITORS FLT3, AURKA, FLT1 ROCK2 473/4885SCD 3962/4885NR1H2 2435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.